Reacx Pharmaceuticals, Inc.

This early-stage study tests the safety of nalmefene implants in 24 healthy adults. Participants receive one or two implants that stay in place for 4 or 12 weeks. Researchers monitor side effects and how the drug moves through the body to plan future studies in people with opioid…